Research Article

You have full text access to this OnlineOpen article

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

  1. Ferdinand C. Breedveld1,†,*,
  2. Michael H. Weisman2,†,
  3. Arthur F. Kavanaugh3,†,
  4. Stanley B. Cohen4,†,
  5. Karel Pavelka5,
  6. Ronald van Vollenhoven6,†,
  7. John Sharp7,†,
  8. John L. Perez8,†,
  9. George T. Spencer-Green8,†

Article first published online: 29 DEC 2005

DOI: 10.1002/art.21519

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 1, pages 26–37, January 2006

Additional Information

How to Cite

Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. v., Sharp, J., Perez, J. L. and Spencer-Green, G. T. (2006), The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism, 54: 26–37. doi: 10.1002/art.21519

Author Information

  1. 1

    Leiden University Medical Center, Leiden, The Netherlands

  2. 2

    Cedars-Sinai Medical Center, Los Angeles, California

  3. 3

    University of California San Diego Center for Innovative Therapy, La Jolla

  4. 4

    University of Texas Southwestern Medical Center, Dallas

  5. 5

    Institute of Rheumatology, Prague, Czech Republic

  6. 6

    Karolinska Hospital, Stockholm, Sweden

  7. 7

    University of Washington, Seattle

  8. 8

    Abbott Laboratories, Parsippany, New Jersey

  1. †

    Dr. Breedveld has received consulting fees or honoraria (less than $10,000 per year) from Centocor, Schering-Plough, Amgen/Wyeth, and Abbott. Dr. Weisman has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Bristol-Myers Squibb, Centocor, Amgen/Wyeth, Roche, Human Genome Sciences, Elan/Biogen, Regeneron, and Genentech. Dr. Kavanaugh has performed clinical studies for Abbott, Amgen, Centocor, Biogen-Idec, Bristol-Myers Squibb, and Genentech. Dr. Cohen has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Genentech, Biogen IDEC, Scios, Amgen, Sanofi-Aventis, Chelsea Therapeutics, and Xencor. Dr. van Vollenhoven has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Centocor, Schering-Plough, and Wyeth. Dr. Sharp has received consulting fees or honoraria (more than $10,000 per year) from Abbott, Amgen, Aventis, Centocor, Fujisawa, and Wyeth and consulting fees or honoraria (less than $10,000 per year) from Bristol-Myers Squibb and Schering. Dr. Perez is a member of Abbott's stock retirement plan. Dr. Spencer-Green owns stock in Abbott.

*Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4-R Postbox 9600, Leiden 2300 RC, The Netherlands

Publication History

  1. Issue published online: 29 DEC 2005
  2. Article first published online: 29 DEC 2005
  3. Manuscript Accepted: 21 SEP 2005
  4. Manuscript Received: 31 MAR 2005

Funded by

  • Abbott Laboratories

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS